Zantac Possibly Linked to Pancreatic Cancer
Zantac Litigation Lawyers in New York
Several recent studies have shown that there could be a link between Zantac, a popular over-the-counter antacid, and pancreatic cancer. Recently, Zantac (ranitidine) was recalled due to the fact that the drug contains N-nitrosodimethylamine, or NDMA, a proven carcinogen. Much Zantac litigation has centered on digestive system cancer, but new information reveals that Zantec could also lead to other forms of cancer, such as pancreatic, prostate, brain, and breast cancer, among others.
If you or a loved one was diagnosed with pancreatic cancer after taking Zantac or a similar rantidine-containing medication, you could be entitled to financial compensation. Currently, Rheingold Giuffra Ruffo & Plotkin LLP is investigating Zantac claims involving pancreatic and other types of cancer. We encourage you to reach out to our firm today to learn more about your legal rights and options.
Contact us online or call (888) 260-0473 for a free case evaluation with one of our Zantac litigation lawyers in New York.
What Is NDMA?
NDMA is an N-nitroso compound (NOC) and it, along with N-nitrosodiethylamine (NDEA), is a known carcinogen. Additionally, NDMA is what is known as “geotoxic,” meaning it can cause immediate cancer growth after entering cellular DNA. Due to its carcinogenic nature, NDMA is strictly regulated and significant human intake is not recommended.
Somewhat surprisingly, NDMA (and NDEA) is the most common NOC found in food. Studies of food-related NDMA intake have revealed a possible link between NDMA and pancreatic cancer. A study conducted by The University of Texas’s MD Anderson Cancer Center concluded that further investigation into the link between NDMA intake and pancreatic cancer was warranted; another study published in the Journal of the National Cancer Institute found the same.
How NDMA Can Cause Pancreatic Cancer
The active ingredient in Zantac and many other over-the-counter and prescription antacid medications is ranitidine. The molecular structure of ranitidine causes it to frequently create NDMA after ingestion during the digestion process.
According to the Federal Drug and Food Administration (FDA), Zantac and its generic counterparts have been found to contain as much as 3,000 to 26,000 times higher NDMA levels than are permitted by law. With long-term exposure, these NDMA levels can prompt cancer growth.
Ranitidine Recalled in the U.S.
In October of 2019, Sanofi (the maker of Zantac) voluntarily recalled over-the-counter Zantac medication in both the U.S. and Canada. In April of this year (2020), the FDA requested that manufacturers of ranitidine products, including Zantac, remove all products from the U.S. market effective immediately in response to numerous studies indicating a link between ranitidine and various cancers.
If you or a loved one was diagnosed with pancreatic cancer after taking Zantac for a prolonged period of time, our firm can help you understand your legal options and work to protect your right to a fair recovery. Our New York Zantac lawsuit attorneys are experienced in defective drug litigation, specifically including Zantac litigation. We understand how to fight back against massive pharmaceutical companies’ wrongful and deceptive practices, all while providing each and every client with the care and attention they need and deserve.
Schedule a free initial consultation today; call (888) 260-0473 or contact us online.